Xilio Therapeutics, Inc.
- XLO
- NASDAQ
- Biotechnology
- Cancer Immunotherapy (Tumor-Selective)
- Oncology Biotech (Checkpoint Inhibitors)
$8.71
Today +1.87%Quote Oct 19, 2026, 03:18 PM UTC
−5.42%over the last month
Max drawdown −7.3%From 1-month high −7.3%3 months −0.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$50.4M
Quote Oct 19
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$98.00
+1025.1% from here
Floor
$8.51
2.3% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about XLOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
76
Founded
2016